Aquinox Pharmaceuticals is a clinical-stage pharmaceutical company discovering and developing therapeutics for chronic urological conditions marked by inflammation and pain. Co.'s primary drug candidate, rosiptor, for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS). Co. is focused on utilizing its library of novel compounds that activate SHIP1 (SH2-containing inositol-5'-phosphatase to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. We show 24 historical shares outstanding datapoints in our coverage of AQXP's shares outstanding history.
Understanding the changing numbers of AQXP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AQXP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AQXP by allowing them to research AQXP shares outstanding history
as well as any other stock in our coverage universe. |
Free AQXP Email Alerts:
Video: Shares Outstanding Importance
